BJMO - volume 18, issue 2, march 2024
D. Schrijvers MD, PhD, S. Mignon MD, M. Brands MD, S. van Roy MD, S. De Schepper MD, N. Van Bruaene MD, D. Nevens MD, PhD, N. Meireson MD
Head and neck cancer is a complex cancer that involves multiple disciplines (surgery, radiotherapy, systemic therapy). The timely start of surgery and radiotherapy is of utmost importance since the time between the start of treatment is related to overall survival. A delay in surgery increases overall mortality by 6%, while a delay in radiotherapy increases overall mortality by 9%. In this article, the importance of a short time to start treatment in patients with head and neck cancer is discussed.
(BELG J MED ONCOL 2024;18(2):46–8)
Read moreBJMO - volume 16, issue 4, june 2022
W. Lybaert MD, R. de Bree MD, PhD, J. Meulemans MD, PhD, J-F. Daisne MD, PhD, F. Duprez MD, PhD, D. Nevens MD, PhD, R. Van Hoeyweghen MD, PhD, K. Boeykens RN , J. De Ceulaer MD, W. Huvenne MD, PhD, O. Lenssen MD
The annual winter meeting of the ‘Vlaamse Werkgroep Hoofd-Hals Tumoren’ on 11 December 2021 handled the different possible de-escalation strategies in the treatment of squamous cell carcinoma of the head and neck region (SCCHN) in anno 2022. Which surgical techniques can be used nowadays to diminish long-term morbidities in SCCHN? To which extent can we lower radiotherapy doses and regions in the treatment planning of SCCHN? Are the systemic treatment options of SCCHN always radical for each patient or more personalised? Is a comprehensive geriatric assessment feasible and already used in our head and neck oncology practice? Last but not least, how can we optimally sustain our patients with nutrition before, during and after treatment of head and neck cancer?
(BELG J MED ONCOL 2022;16(4):198–208)
Read moreBJMO - volume 14, issue 4, june 2020
M. Machiels MD, PhD, D. Nevens MD, PhD, K. Erven MD, PhD, G. Buelens MD, C. Billiet MD, PhD, Y. Geussens MD, P. Janssens MD, S. Vanderkam MD, R. Weytjens MD
Whole-breast irradiation, as part of breast-conservation therapy (BCT), has been well-established the last decades. Nonetheless, most local recurrences found after BCT are within or close to the tumour bed. This led to the concept of partial breast irradiation (PBI), delivering the radiation dose to a decreased target volume, thereby lowering exposure to the organs at risk and hence potentially minimizing late adverse effects. This became increasingly important with growing survivorship of patients with early-stage breast cancer over the past decades and the consideration of late adverse effects is gaining more importance. In this review, we will present an overview of the current literature, techniques to deliver PBI and we try to establish whether there is a place for PBI in early-stage breast cancer treatment.
(BELG J MED ONCOL 2020;14(4):140–45)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
